KATHARINE INGRAM: Open Payments
NPI 1871208462 · BALTIMORE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$651 in 31 payments from 17 companies in 2025. Trend: 2023 $306 · 2024 $592 · 2025 $651
Food & beverage: $651
| Company | Payments | Amount |
|---|---|---|
| PFIZER INC. | 7 | $151 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $95 |
| Otsuka America Pharmaceutical, Inc. | 3 | $64 |
| Lundbeck LLC | 2 | $47 |
| ABBVIE INC. | 2 | $40 |
| Lilly USA, LLC | 2 | $35 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $29 |
| GlaxoSmithKline, LLC. | 1 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $26 |
| Phathom Pharmaceuticals, Inc. | 1 | $20 |
Products named: NURTEC ODT, REXULTI, CAPLYTA, JARDIANCE, Kerendia, TRELEGY ELLIPTA, TRINTELLIX, QULIPTA.
Industry payments across MD — which companies pay providers there.
